Your browser doesn't support javascript.
Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022.
Stoliaroff-Pepin, Anna; Peine, Caroline; Herath, Tim; Lachmann, Johannes; Perriat, Delphine; Dörre, Achim; Nitsche, Andreas; Michel, Janine; Grossegesse, Marica; Hofmann, Natalie; Rinner, Thomas; Kohl, Claudia; Brinkmann, Annika; Meyer, Tanja; Dorner, Brigitte G; Stern, Daniel; Treindl, Fridolin; Hein, Sascha; Werel, Laura; Hildt, Eberhard; Gläser, Sven; Schühlen, Helmut; Isner, Caroline; Peric, Alexander; Ghouzi, Ammar; Reichardt, Annette; Janneck, Matthias; Lock, Guntram; Schaade, Lars; Wichmann, Ole; Harder, Thomas.
  • Stoliaroff-Pepin A; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany. Electronic address: Stoliaroff-PepinA@rki.de.
  • Peine C; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany. Electronic address: PeineC@rki.de.
  • Herath T; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.
  • Lachmann J; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.
  • Perriat D; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.
  • Dörre A; Department for Infectious Disease Epidemiology, Robert Koch Institute, Germany.
  • Nitsche A; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Michel J; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Grossegesse M; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Hofmann N; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Rinner T; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Kohl C; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Brinkmann A; Centre for Biological Threats and Special Pathogens, ZBS1 Highly Pathogenic Viruses, Robert Koch Institute, Germany.
  • Meyer T; Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.
  • Dorner BG; Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.
  • Stern D; Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.
  • Treindl F; Centre for Biological Threats and Special Pathogens, ZBS3 Biological Toxins, Robert Koch Institute, Germany.
  • Hein S; Division Virology, Paul-Ehrlich-Institute, Germany.
  • Werel L; Division Virology, Paul-Ehrlich-Institute, Germany.
  • Hildt E; Division Virology, Paul-Ehrlich-Institute, Germany.
  • Gläser S; Klinik für Innere Medizin - Pneumologie und Infektiologie, Vivantes Klinikum Neukölln und Spandau, Berlin, Germany.
  • Schühlen H; Vivantes Netzwerk für Gesundheit GmbH, Direktorat Klinische Forschung & Akademische Lehre, Berlin, Germany.
  • Isner C; Klinik für Innere Medizin - Infektiologie, Vivantes Auguste-Viktoria-Klinikum, Rubensstr. 125, 12157 Berlin, Germany.
  • Peric A; Klinik für Pneumologie und Infektiologie, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin, Germany.
  • Ghouzi A; Schön Klinik Düsseldorf, Interdisziplinäre Notaufnahme, Am Heerdter Krankenhaus 2, 40549 Düsseldorf, Germany.
  • Reichardt A; Helios Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany.
  • Janneck M; Klinik für Kardiologie, Sektion Nephrologie, Albertinen Krankenhaus, Süntelstraße 11a, 22457 Hamburg, Germany.
  • Lock G; Klinik für Innere Medizin, Albertinen Krankenhaus, Süntelstraße 11a, 22457 Hamburg, Germany.
  • Schaade L; Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Germany.
  • Wichmann O; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.
  • Harder T; Department for Infectious Disease Epidemiology, Immunization Unit, Robert Koch Institute, Germany.
Vaccine ; 41(2): 290-293, 2023 01 09.
Article in English | MEDLINE | ID: covidwho-2245460
ABSTRACT
We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE was 89 % (95 % CI 84-93 %) overall, 79 % in patients with more than two comorbidities and 77 % in adults aged 60-75 years. A third dose increased the VE to more than 93 % in all patient-subgroups.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Adult / Humans Country/Region as subject: Europa Language: English Journal: Vaccine Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Adult / Humans Country/Region as subject: Europa Language: English Journal: Vaccine Year: 2023 Document Type: Article